PM can almost always be improved or prevented with anti-inflammatory drugs and DM is sometimes improved with anti-inflammatory drugs, but anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive ILD is sometimes unimproved by such agents and follows a rapidly progressive (RP) course. Here, IFIH1 is linked to dermatomyositis.